Predictors of Genetic Testing for Hereditary Cancer in Qualified Individuals Genetic testing for hereditary cancer risk
Main Article Content
Abstract
Introduction and Methods: We surveyed individuals in the United States whose personal and/or family history met clinical criteria for genetic testing for cancer susceptibility. Using univariate and multivariable logistic regression analyses, we examined demographic and clinical factors associated with self-reported receipt of clinical genetic testing.
Results: Of the 1,269 respondents with personal and/or family history meeting clinical criteria for genetic testing, 48.1% reported having undergone clinical genetic testing. Testing uptake varied by cancer type (p<0.05) and was highest among individuals with personal diagnoses of breast (73.9%), ovarian (88.2%), and pancreatic (70.2%) cancers, as compared with prostate cancer (33.6%). Females were significantly more likely than males to have undergone genetic testing (odds ratio, OR, 1.67, CI: 1.17-2.37), and people 70 years or older were less likely to have had testing when compared with those age under 50 (OR 0.33, CI: 0.22-0.48). Individuals who were diagnosed with cancer 15 or more years ago were less likely to have had genetic testing than those with more recent cancer diagnoses (OR 0.47 CI: 0.30-0.74). Individuals who were eligible to receive genetic testing based on their family history of cancer alone were less likely to have had testing than those with a personal cancer diagnosis (OR 0.65, CI: 0.44-0.97).
Conclusion: While clinical genetic testing is routinely offered to specific groups of patients at risk for hereditary cancer syndromes (especially those with a personal or family history of breast and/or ovarian cancers), uptake remains low among men and among individuals who qualify for genetic testing based on diagnoses of non-gynecologic cancers and/or family history alone. Patient- and clinician-facing interventions are needed to raise awareness of indications for clinical genetic testing for cancer susceptibility.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Win AK, Jenkins MA, Dowty JG, et al. Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. Mar 2017;26(3):404-412. doi:10.1158/1055-9965.EPI-16-0693
3. Daly MB, Pal T, Maxwell KN, et al. NCCN Guidelines(R) Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024. J Natl Compr Canc Netw. Oct 202 3;21(10):1000-1010. doi:10.6004/jnccn.2023.0051
4. Weiss JM, Gupta S, Burke CA, et al. NCCN Guidelines(R) Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021. J Natl Compr Canc Netw. Oct 15 2021;19(10):1122-1132. doi:10.1164/jnccn.2021.0048
5. Yoshida R. Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer. Nov 2021;28(6):1167-1180. doi:10.1007/s1 2282-020-01148-2
6. Ceyhan-Birsoy O, Jayakumaran G, Kemel Y, et al. Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients. Genome Med. Aug 15 2022;14(1):92. doi:10.1186/s13073-022-01101-2
7. Heald B, Mokhtary S, Nielsen SM, et al. Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer. Gynecol Oncol. Aug 2022;166(2):344-350. doi:10.1016/j.ygyno.2022.05.023
8. Uson PLS, Jr., Samadder NJ, Riegert-Johnson D, et al. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. Clin Transl Gastroenterol. Oct 8 2021;12(10) :e00414. doi:10.14309/ctg.0000000000000414
9. Yurgelun MB, Kulke MH, Fuchs CS, et al. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol. Apr 1 2017;35(10): 1086-1095. doi:10.1200/JCO.2016.71.0012
10. Kurian AW, Griffith KA, Hamilton AS, et al. Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer. JAMA. Feb 7 2017;317(5):531-534. doi:10.1001/jama.2016.16918
11. Lin J, Sharaf RN, Saganty R, et al. Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis. Gynecol Oncol. Aug 2021;162(2):506-516. doi:10.1016/j.ygyno.2021.05.011
12. Walker EJ, Carnevale J, Pedley C, et al. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer. Apr 2019;18(2):241-251. doi:10.1007/s10689-018-0106-2
13. Muller C, Lee SM, Barge W, et al. Low Referral Rate for Genetic Testing in Racially and Ethnically Diverse Patients Despite Universal Colorectal Cancer Screening. Clin Gastroenterol Hepatol. Dec 2018; 16(12):1911-1918 e2. doi:10.1016/j.cgh.2018.08.038
14. Suri Y, Yasmeh JP, Basu A. Understanding the Uptake and Challenges of Genetic Testing Guidelines for Prostate Cancer Patients. Cancer Treat Res Commun. 2022;32:100588. doi:10.1016/ j.ctarc.2022.100588
15. Loeb S, Li R, Sanchez Nolasco T, et al. Barriers and facilitators of germline genetic evaluation for prostate cancer. Prostate. Aug 2021;81(11):754-764. doi:10.1002/pros.24172
16. Austin S, Hanson EN, Delacroix E, et al. Impact of barriers and motivators on intention and confidence to undergo hereditary cancer genetic testing. J Genet Couns. May 27 2024;doi:10.1002/ jgc4.1926
17. Dusic EJ, Theoryn T, Wang C, Swisher EM, Bowen DJ, Team ES. Barriers, interventions, and recommendations: Improving the genetic testing landscape. Front Digit Health. 2022;4:961128. doi:10.3389/fdgth.2022.961128
18. Smith-Uffen M, Bartley N, Davies G, Best M. Motivations and barriers to pursue cancer genomic testing: A systematic review. Patient Educ Couns. Jun 2021;104(6):1325-1334. doi:10.1016/j.pec.2020.12.024
19. Doran EaA, B. Surveillance Data from the Hereditary Cancer Network, 2016-2020. 2023. https://www.michigan.gov/mdhhs/-/media/Project/Websites/mdhhs/Keeping-Michigan- Healthy/Chronic-Disease-Epidemiology/Cancer-Genomics-Epi/Surveillance-Reports_HCN- Database/Surveillance-Data-from-the-Hereditary-Cancer-Network-HCN-Database- 20162020.pdf?rev=2f6dfa9ed80746a986ea1eb2d01f71de&hash=B5B462A1E3E0CDB56C573C A8139B0888
20. Gerido LH, Griggs JJ, Resnicow K, et al. The Michigan Genetic Hereditary Testing (MiGHT) study's innovative approaches to promote uptake of clinical genetic testing among cancer patients: a study protocol for a 3-arm randomized controlled trial. Trials. Feb 10 2023;24(1):105. doi:10.1186/ s13063-023-07125-2
21. Kastrinos F, Uno H, Ukaegbu C, et al. Development and Validation of the PREMM(5) Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol. Jul 1 2017;35(19): 2165-2172. doi:10.1200/JCO.2016.69.6120
22. Mercado RC, Hampel H, Kastrinos F, et al. Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. Genet Med. Jul 2012; 14(7):670-80. doi:10.1038/gim.2012.18
23. Ladd MK, Peshkin BN, Isaacs C, et al. Predictors of genetic testing uptake in newly diagnosed breast cancer patients. J Surg Oncol. Aug 2020;122(2):134-143. doi:10.1002/jso.25956
24. Kurian AW, Abrahamse P, Furgal A, et al. Germline Genetic Testing After Cancer Diagnosis. JAMA. Jul 3 2023;330(1):43-51. doi:10.1001/jama. 2023.9526
25. My Family Health Portrait. NIH NHGRI. Accessed 3/27/2024, 2024. https://cbiit.github.io/FHH/html/index.html#
26. Samadder NJ, Riegert-Johnson D, Boardman L, et al. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. JAMA Oncol. Feb 1 2021;7(2):230-237. doi:10.1001/jama oncol.2020.6252
27. Syed H, Sommovilla J, Burke CA, et al. Referral, Uptake, and Outcome of Genetic Counseling and Testing in Patients With Early-Onset Colorectal Cancer. J Natl Compr Canc Netw. Nov 2023;21(11):1156-1163 e5. doi:10.6004/jnccn. 2023.7057
28. Barcenas CH, Shafaee MN, Sinha AK, et al. Genetic Counseling Referral Rates in Long- Term Survivors of Triple-Negative Breast Cancer. J Natl Compr Canc Netw. May 2018;16(5):518-524. doi: 10.6004/jnccn.2018.7002
29. Barrus K, Purington N, Chun N, Ladabaum U, Ford JM. Somatic tumor testing implications for Lynch syndrome germline genetic testing. Cancer Genet. Jun 2022;264-265:16-22. doi:10.1016/j.can cergen.2022.02.010
30. Dallagiovanna C, Filippi F, Riccaboni A, et al. The neglected role of preimplantation genetic testing for Lynch syndrome. Reprod Biomed Online. Mar 2023;46(3):421-423. doi:10.1016/j.rbm o.2022.12.001
31. Somigliana E, Costantini MP, Filippi F, et al. Fertility counseling in women with hereditary cancer syndromes. Crit Rev Oncol Hematol. Mar 2022;171:103604. doi:10.1016/j.critrevonc.2022.103604
32. Evans DG, Maher ER, Macleod R, Davies DR, Craufurd D. Uptake of genetic testing for cancer predisposition. J Med Genet. Sep 1997;34(9):746-8. doi:10.1136/jmg.34.9.746
33. Swoboda CM, Wijayabahu AT, Fareed N. Attitudes towards and sociodemographic determinants of genetic test usage in the USA; data from the Health Information National Trend Survey, 2020. J Genet Couns. Feb 2023;32(1):57-67. doi: 10.1002/jgc4.1620
34. Frey MK, Finch A, Kulkarni A, Akbari MR, Chapman-Davis E. Genetic Testing for All: Overcoming Disparities in Ovarian Cancer Genetic Testing. Am Soc Clin Oncol Educ Book. Apr 2022; 42:1-12. doi:10.1200/EDBK_350292
35. Nishimura Y, Acoba JD. Impact of Breast Cancer Awareness Month on Public Interest in the United States between 2012 and 2021: A Google Trends Analysis. Cancers (Basel). May 21 2022; 14(10)doi:10.3390/cancers14102534
36. Waltz M, Cadigan RJ, Prince AER, Skinner D, Henderson GE. Age and perceived risks and benefits of preventive genomic screening. Genet Med. Sep 2018;20(9):1038-1044. doi:10.1038/gim. 2017.206